Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review

Combination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review

Blog Article

Advancements in the specific therapy of pulmonary arterial hypertension (PAH) and new combination therapy strategies and escalation treatment over the past decade have significantly improved disease j&d manufacturing website control, slowed its progression, and improved quality of life and patient survival.This review provides a detailed discussion of current strategies for PAH-specific therapy available in the Russian Federation for patients with classical and non-classical PAH who fail to achieve treatment medicator pump goals and remain at intermediate risk of disease progression/mortality.